Poland· PL-100313902
Vipdomet
A metformin and alogliptin product containing metformini hydrochloridum + alogliptinum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Metformin and alogliptin is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD13 (metformin and alogliptin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Metformin and alogliptin · ATC A10BD13
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Metformini hydrochloridum + Alogliptinum
- Manufacturer
- Takeda Pharma A/S
- Country
- Poland (PL)
- ATC code
- A10BD13
- ATC class
- Metformin and alogliptin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and alogliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and alogliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and alogliptin in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAlogliptin 12.5mg / Metformin 1g tabletsNiche Pharma Ltd
- SpainVIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULATakeda Pharma A/S
- CanadaKAZANOTAKEDA CANADA INC
- IcelandVipdometTakeda Pharma A/S*
- NetherlandsVipdomet 12,5 mg/ 1000 mg filmomhulde tabletTakeda Pharma A/S
- SwedenVipdomet 12,5 mg/1000 mg Filmdragerad tablettTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vipdomet
- Liechtenstein · Vipdomet
- Norway · Vipdomet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f2970f9d-6cc7-49e6-9107-65e1c3446dcc GET /v1/drugs/f2970f9d-6cc7-49e6-9107-65e1c3446dcc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "1000 mg + 12,5 mg",
"packaging": "Rp ¦ EU/1/13/843/013 ¦ 90604\n10 tabl.\nRp ¦ EU/1/13/843/014 ¦ 90605\n14 tabl.\nRp ¦ EU/1/13/843/015 ¦ 90606\n20 tabl.\nRp ¦ EU/1/13/843/016 ¦ 90607\n28 tabl.\nRp ¦ EU/1/13/843/017 ¦ 90608\n56 tabl.\nRp ¦ EU/1/13/843/018 ¦ 90609\n60 tabl.\nRp ¦ EU/1/13/843/019 ¦ 90610\n98 tabl.\nRp ¦ EU/1/13/843/020 ¦ 90611\n112 tabl.\nRp ¦ EU/1/13/843/021 ¦ 90612\n120 tabl.\nRp ¦ EU/1/13/843/022 ¦ 90613\n180 tabl.\nRp ¦ EU/1/13/843/023 ¦ 90614\n196 tabl.\nRp ¦ EU/1/13/843/024 ¦ 90615\n200 tabl.\nRp ¦ EU/1/13/843/026 ¦ 122317\n198 tabl. (2 x 98)",
"substance": "Metformini hydrochloridum 1000 mg + Alogliptinum 12.5 mg",
"common_name": "Metformini hydrochloridum + Alogliptinum",
"pl_product_id": "100313902",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about metformin and alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.